Identification of the first Rho–GEF inhibitor, TRIPα, which targets the RhoA‐specific GEF domain of Trio
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The Rho–guanine nucleotide exchange factors (Rho–GEFs) remodel the actin cytoskeleton via their Rho–GTPase targets and affect numerous physiological processes such as transformation and cell motility. They are therefore attractive targets to design specific inhibitors that may have therapeutic applications. Trio contains two Rho–GEF domains, GEFD1 and GEFD2, which activate the Rac and RhoA pathways, respectively. Here we have used a genetic screen in yeast to select in vivo peptides coupled to thioredoxin, called aptamers, that could inhibit GEFD2 activity. One aptamer, TRIAPα (TRio Inhibitory APtamer), specifically blocks GEFD2‐exchange activity on RhoA in vitro. The corresponding peptide sequence, TRIPα, inhibits TrioGEFD2‐mediated activation of RhoA in intact cells and specifically reverts the neurite retraction phenotype induced by TrioGEFD2 in PC12 cells. Thus TRIPα is the first Rho–GEF inhibitor isolated so far, and represents an important step in the design of inhibitors for the expanding family of Rho–GEFs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brefeldin A Acts to Stabilize an Abortive ARF–GDP–Sec7 Domain Protein Complex
Peyroche, A., Antonny, B., Robineau, S., Acker, J., Cherfils, J., & Jackson, C. L. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80455-4 · Cited by 453
Cited by
Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?
Vigil, D., Cherfils, J., Rossman, K. L., & Der, C. J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2960 · Cited by 819
Konstantinopoulos, P. A., Karamouzis, M. V., & Papavassiliou, A. G. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2221 · Cited by 451
Structural snapshots of the mechanism and inhibition of a guanine nucleotide exchange factor
Renault, L., Guibert, B., & Cherfils, J. (2003) · Nature · doi:10.1038/nature02197 · Cited by 320
RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer
Yan, C., & Theodorescu, D. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014415 · Cited by 119
“Nevertheless, inhibitors have been developed that specifically target GEF proteins of the RAS family small GTPases, including ARF, RHO, and RAC1 (Schmidt et al., 2002; Renault et al., 2003; Gao et al., 2004).”
BackgroundAuto-inhibition of the Dbl Family Protein Tim by an N-terminal Helical Motif
Yohe, M. E., Rossman, K. L., Gardner, O. S., Karnoub, A. E., Snyder, J. T., Gershburg, S., Graves, L. M., Der, C. J., & Sondek, J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700185200 · Cited by 45
Metadata
- Authors
- Schmidt, S., Diriong, S., Méry, J., Fabbrizio, E., & Debant, A.
- Venue
- FEBS Letters
- Publisher
- Wiley
- Published
- 2002-06-13
- Volume
- 523
- Issue
- 1-3
- Pages
- 35-42
- ISSN
- 0014-5793 (ISSN-L)
- 1873-3468
- OpenAlex
- W1997140988
- Cited by
- 71
- References
- 1
- FWCI
- 1.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification of the first Rho–GEF inhibitor, TRIPα, which targets the RhoA‐specific GEF domain of Trio. https://app.cochat.ai/papers/10.1016/s0014-5793(02)02928-9
- The paper
- Schmidt, S., Diriong, S., Méry, J., Fabbrizio, E., & Debant, A. (2002). Identification of the first Rho–GEF inhibitor, TRIPα, which targets the RhoA‐specific GEF domain of Trio. FEBS Letters. https://doi.org/10.1016/s0014-5793(02)02928-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.